Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Completed

Conditions: Psoriasis; Type 2 Diabetes

Treatments: Drug: GLP-1 analog

Study type: Interventional

Funder types: Other

Identifiers

NCT01687582

UCL-DIAB-02

Details and patient eligibility

About

The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.

Full description

The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.

Enrollment: 10 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments.

Exclusion criteria

• Type 1 diabetes
• Secondary diabetes
• Liver, renal or pancreatic disease
• Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

GLP-1 analog

Experimental group

Description:

Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.

Treatment:

Drug: GLP-1 analog